Viracta Therapeutics, Inc. operates as a precision oncology firm, specializing in the development of therapeutic agents aimed at treating cancers linked to viral infections. The company's leading drug candidate, Nana-val (a combination of nanatinostat and valganciclovir), is currently advancing through multiple clinical trials. It is in Phase II development for Epstein-Barr virus-positive (EBV+) lymphoma.
| Date | Est. | Actual | |
|---|---|---|---|
| Nov 13, 2024 | -$0.21 | -$0.27 | Miss |
| Aug 14, 2024 | -$0.35 | -$0.25 | Beat |
| May 9, 2024 | -$0.35 | -$0.23 | Beat |
| Mar 7, 2024 | -$0.30 | -$0.35 | Miss |
| Nov 9, 2023 | -$0.33 | -$0.33 | Beat |
| Aug 14, 2023 | -$0.30 | -$0.32 | Miss |